Raaphorst G P, Feeley M M, Heller D P, Danjoux C E, Martin L, Maroun J A, De Sanctis A J
Ottawa Regional Cancer Centre, Ontario, Canada.
Anticancer Res. 1990 Jul-Aug;10(4):923-7.
Lonidamine combined with cisplatin treatment was tested in human glioma (U87MG) human squamous cell carcinoma (UMSCCl) and Chinese hamster (HA1) cells. The order of sensitivity to cisplatin was HA1 greater than U87MG greater than UMSCCl. Lonidamine caused little sensitization in U87MG cells, moderate sensitization in HA1 cells and large sensitization in UMSCCl cells. The degree of sensitization was correlated to the effect of lonidamine on cell growth. The degree of sensitization to cisplatin by lonidamine treatment was dependent on lonidamine exposure concentration, time and treatment sequence. Lonidamine shows potential for enhancement of cisplatin chemotherapy but this appears to be cell type specific and should be tested for cells derived from sites of clinical interest for such drug therapy.
在人胶质瘤（U87MG）、人鳞状细胞癌（UMSCCl）和中国仓鼠（HA1）细胞中测试了氯尼达明联合顺铂治疗。对顺铂的敏感顺序为HA1大于U87MG大于UMSCCl。氯尼达明在U87MG细胞中引起的致敏作用较小，在HA1细胞中引起中度致敏，在UMSCCl细胞中引起高度致敏。致敏程度与氯尼达明对细胞生长的影响相关。氯尼达明治疗对顺铂的致敏程度取决于氯尼达明的暴露浓度、时间和治疗顺序。氯尼达明显示出增强顺铂化疗的潜力，但这似乎具有细胞类型特异性，应该针对此类药物治疗临床相关部位来源的细胞进行测试。
